NLS Drug Development Pharma

Novo Nordisk announced that Switzerland is the first country to launch Xultophy® (IDegLira) for people with type 2 diabetes.  Xultophy® is the first combination of a basal insulin [Tresiba® (insulin degludec)] and a GLP-1 analogue [Victoza® (liraglutide)]. Xultophy® is administered as a single injection once a day independently of meals.  It is intended for use in adults with type 2 diabetes who […]

Two months after its own deadline, the U.S. Food and Drug Administration (FDA) issued approval for Novo Nordisk’s first weight-loss therapy.  Approved was Novo’s Saxenda for use in managing weight in conjunction with diet and exercise. Saxenda is a higher dose of the diabetes treatment liraglutide. The drug is indicated for patients who qualify as […]

The European Medicines Agency (EMA) recommended the highest number of orphan designated medicines for marketing authorization in a single year in 2014. Out of the 82 medicines for human use recommended last year, 17 are meant for the treatment of a rare disease, serving patients who frequently have a few or no treatment options. Among […]

Biopharmaceutical firm Lundbeck A/S announced that it would discontinue future research into its experimental stroke drug compound desmoteplase, despite two previous studies showing positive patient effects and fast-track designation from the U.S. Food and Drug Administration (FDA) for the treatment of acute ischemic stroke. Lundbeck would take a write down of $51.26 million for the […]

Just two days after the Danish company’s Lundbeck CEO stepped down for an ethics lapse, the UK’s National Institute for Health and Care Excellence (NICE) gave Selincro (namelfene) approval in final draft guidance, meaning the country’s National Health Service will make funding available for the £42.42-per-14-tablet-pack medication within three months. “We are pleased to be able […]

Xellia Pharmaceuticals (‘Xellia’), a specialty pharmaceutical company focusing on providing important anti-infective treatments against